View Item 

Show simple item record

Immunosuppressive treatment in multifocal motor neuropathy
dc.contributor.authorFeldman, Eva L.en_US
dc.contributor.authorBromberg, Mark B.en_US
dc.contributor.authorAlbers, James W.en_US
dc.contributor.authorPestronk, Alanen_US
dc.date.accessioned2007-04-06T18:53:57Z
dc.date.available2007-04-06T18:53:57Z
dc.date.issued1991-09en_US
dc.identifier.citationFeldman, Eva L.; Bromberg, Mark B.; Albers, James W.; Pestronk, Alan (1991)."Immunosuppressive treatment in multifocal motor neuropathy." Annals of Neurology 30(3): 397-401. <http://hdl.handle.net/2027.42/50344>en_US
dc.identifier.issn0364-5134en_US
dc.identifier.issn1531-8249en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/50344
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=1952828&dopt=citationen_US
dc.description.abstractWe report the results of immunosuppressive treatments of 13 patients with multifocal motor neuropathy and elevated titers of serum antibodies to the GM1 ganglioside. All patients failed to respond to oral prednisone. There was no clinical response in 4 patients treated with plasma exchange. Nine patients received cyclophosphamide, with clinical improvement and fall in antibody titers in 8. In 3 patients, cyclophosphamide was discontinued with ensuing clinical relapse and rise in the titers of serum anti-GM1 antibodies. These patients provide further evidence for the efficacy of cyclophosphamide therapy in patients with multifocal motor neuropathy.en_US
dc.format.extent468423 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherLife and Medical Sciencesen_US
dc.subject.otherNeuroscience, Neurology, and Psychiatryen_US
dc.titleImmunosuppressive treatment in multifocal motor neuropathyen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPsychiatryen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Neurology, University of Michigan, Ann Arbor, MI ; 1120C Neuroscience Laboratory Building, 1103 E. Huron Street, Ann Arbor, MI 48109-1687en_US
dc.contributor.affiliationumDepartment of Neurology, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationumDepartment of Neurology, University of Michigan, Ann Arbor, MIen_US
dc.contributor.affiliationotherDepartment of Neurology, Washington University School of Medicine, St Louis, MOen_US
dc.identifier.pmid1952828en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/50344/1/410300312_ftp.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1002/ana.410300312en_US
dc.identifier.sourceAnnals of Neurologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
410300312_ftp.pdf
Size:
457.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.